As New Jersey’s only NCI-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health, provides patients access to the most advanced treatment options including complex surgical procedures, sophisticated radiation therapy techniques, innovative clinical trials, immunotherapy, and precision medicine.
|
|
|
$1.6 Million NCI Grant Supports New Cancer Education Opportunity |
|
|
|
With the support of the National Cancer Institute, Rutgers Cancer Institute of New Jersey has established the Rutgers Youth Enjoy Science (RUYES) Program, an educational opportunity to encourage underrepresented minority undergraduate and high school students to pursue cancer research and healthcare careers. RUYES seeks to increase the diversity of the biomedical, cancer research workforce in order to reduce cancer disparities in both New Jersey and across the United States. Sunita Chaudhary, PhD, director of research education at Rutgers Cancer Institute is the leader of the program, which is also offered to science teachers from high schools with significant proportions of students from underrepresented backgrounds. Learn more
|
|
Exploring Stress and Poor Health-Related Quality of Life Issues in African American Breast Cancer Survivors |
|
|
|
Researchers at Rutgers University recently conducted a study to determine the association of pre-diagnostic allostatic load, which is a composite measure of cumulative physiological stress and wear and tear on the body, with health-related quality of life in female African American and Black survivors of breast cancer. Adana A.M. Llanos, PhD, MPH of Rutgers Cancer Institute of New Jersey and Rutgers School of Public Health is the senior and corresponding author of this work, along with author Elisa V. Bandera, MD, PhD of Rutgers Cancer Institute, Rutgers School of Public Health and Robert Wood Johnson Medical School. Learn more about the findings published in Breast Cancer Research and Treatment.
|
|
Studying Patterns of Relapse in Pediatric Hodgkin Lymphoma |
|
|
|
New research from Rutgers Cancer Institute of New Jersey suggests that response-based consolidation with modern radiation therapy appears to be a safe and effective standard of care for high-risk pediatric Hodgkin lymphoma patients. This work is led by Rahul R. Parikh, MD, radiation oncologist at Rutgers Cancer Institute and director of the Laurie Proton Therapy Center at Robert Wood Johnson University Hospital, an RWJBarnabas Health facility, as part of a phase 3 study from the Children’s Oncology Group. Learn more about the work that was recently presented at the Annual Meeting of the American Society for Radiation Oncology (ASTRO).
|
|
Recognizing Rutgers Cancer Institute Research Pharmacy |
|
|
|
Members of the Research Pharmacy at Rutgers Cancer Institute of New Jersey play a vital role in patient care and research. Executive director of Oncology Pharmacy Services, Michael P. Kane, RPh, BCOP and his team of Board Certified Oncology (BCOP) Pharmacists and certified pharmacy technicians hold a level of knowledge beyond traditional pharmacy practice that allows them to work side by side with patients and other members of a patient’s cancer care team. Learn more about this unique role.
|
|
Examining Disparities in Triple Negative Breast Cancer |
|
|
|
Triple-negative breast cancer (TNBC) is an aggressive from of breast cancer that is known to have a higher prevalence and worse prognosis in younger African American women and those of African descent. Coral Omene, MD, PhD, is a medical oncologist at Rutgers Cancer Institute of New Jersey and assistant professor of medicine at Rutgers Robert Wood Johnson Medical School, whose clinical expertise focuses on triple negative breast cancer and other forms of breast cancer and translational research and clinical trials. She shares more about TNBC, disparities in this subtype of the disease, and current research on this topic. Read more
|
|
|
|
|
|
|
